Patel JK, Didolkar MS, Pickren JW, Moore RH (1978) Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 135:807–810

CAS  PubMed  Google Scholar 

Kluger HM, Chiang V, Mahajan A et al (2019) Long-Term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial. J Clin Oncol 37:52–60

CAS  PubMed  Google Scholar 

Tawbi HA, Forsyth PA, Algazi A et al (2018) Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 379:722–730

CAS  PubMed  PubMed Central  Google Scholar 

Davies MA, Liu P, McIntyre S et al (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117:1687–1696

PubMed  Google Scholar 

Lehrer EJ, McGee HM, Sheehan JP, Trifiletti DM (2021) Integration of immuno-oncology with stereotactic radiosurgery in the management of brain metastases. J Neurooncol 151:75–84

PubMed  Google Scholar 

Anderson ES, Postow MA, Wolchok JD et al (2017) Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. J Immunother Cancer 5:76

PubMed  PubMed Central  Google Scholar 

Diao K, Bian SX, Routman DM et al (2018) Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity. J Neurooncol 139:421–429

CAS  PubMed  PubMed Central  Google Scholar 

Patel KR, Shoukat S, Oliver DE et al (2017) Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol 40:444–450

CAS  PubMed  Google Scholar 

Kaidar-Person O, Zagar TM, Deal A et al (2017) The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: the potential impact of immunotherapy. Anticancer Drugs 28:669–675

CAS  PubMed  Google Scholar 

Pires da Silva I, Glitza IC, Haydu LE et al (2019) Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment Cell Melanoma Res 32:553–563

CAS  PubMed  Google Scholar 

Schvartsman G, Ma J, Bassett RL Jr et al (2019) Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma. Cancer 125:4193–4202

CAS  PubMed  Google Scholar 

Cohen-Inbar O, Shih H-H, Xu Z et al (2017) The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab. J Neurosurg 127:1007–1014

PubMed  Google Scholar 

Lehrer EJ, Kowalchuk RO, Gurewitz J et al (2023) Concurrent administration of immune checkpoint inhibitors and single fraction stereotactic radiosurgery in patients with non-small cell lung cancer, melanoma, and renal cell carcinoma brain metastases. Int J Radiat Oncol Biol Phys 116:858–868

PubMed  Google Scholar 

Lu VM, Goyal A, Rovin RA et al (2019) Concurrent versus non-concurrent immune checkpoint Inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis. J Neurooncol 141:1–12

PubMed  Google Scholar 

Schnurman Z, Mashiach E, Link KE et al (2023) Causes of death in patients with brain metastases. Neurosurgery 93:986–993

PubMed  Google Scholar 

Link KE, Schnurman Z, Liu C et al (2024) Longitudinal deep neural networks for assessing metastatic brain cancer on a large open benchmark. Nat Commun 15:8170

CAS  PubMed  PubMed Central  Google Scholar 

Larkin J, Chiarion-Sileni V, Gonzalez R et al (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381:1535–1546

CAS  PubMed  Google Scholar 

Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723

CAS  PubMed  PubMed Central  Google Scholar 

Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532

CAS  PubMed  Google Scholar 

Badrigilan S, Meola A, Chang SD et al (2023) Stereotactic radiosurgery with immune checkpoint inhibitors for brain metastases: a meta-analysis study. Br J Neurosurg 37:1533–1543

PubMed  Google Scholar 

Tracz JA, Donnelly BM, Ngu S et al (2023) The abscopal effect: inducing immunogenicity in the treatment of brain metastases secondary to lung cancer and melanoma. J Neurooncol 163:1–14

CAS  PubMed  Google Scholar 

Bodensohn R, Werner S, Reis J et al (2023) Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis. Clin Transl Radiat Oncol 39:100573

CAS  PubMed  PubMed Central  Google Scholar 

Long GV, Atkinson V, Lo SN et al (2025) Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study. Lancet Oncol. https://doi.org/10.1016/S1470-2045(24)00735-6

Article  PubMed  Google Scholar